Top

Clinical Reviews in Allergy & Immunology

Published in:

01-02-2018

Cutaneous Granulomatosis: a Comprehensive Review

Authors: Benedetta Terziroli Beretta-Piccoli, Carlo Mainetti, Marie-Astrid Peeters, Emmanuel Laffitte

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2018

Abstract

Cutaneous granulomatosis is a heterogeneous group of diseases, characterized by a skin inflammatory reaction triggered by a wide variety of stimuli, including infections, foreign bodies, malignancy, metabolites, and chemicals. From a pathogenic point of view, they are divided into non-infectious and infectious granulomas. Pathophysiological mechanisms are still poorly understood. Non-infectious granulomatous skin diseases include granuloma annulare, necrobiosis lipoidica, rheumatic nodules, foreign body granulomas, cutaneous sarcoidosis, and interstitial granulomatous dermatitis. Necrobiosis lipoidica is more frequent in diabetic patients. Infectious granulomas of the skin are caused by mycobacteria, in particular Mycobacterium tuberculosis or atypical mycobacteria; parasites, such as Leishmania; or fungi. Pathogenic mechanisms of M. tuberculosis-related granuloma are discussed. From a clinical point of view, it is useful to divide cutaneous granulomatosis into localized and more disseminated forms, although this distinction can be sometimes artificial. Three types of localized granulomatous lesions can be distinguished: palisaded granulomas (granuloma annulare, necrobiosis lipoidica, and rheumatoid nodules), foreign body granulomas, and infectious granulomas, which are generally associated with localized infections. Disseminated cutaneous granulomas can be divided into infectious, in particular tuberculosis, and non-infectious forms, among which sarcoidosis and interstitial granulomatous dermatitis. From a histological point of view, the common denominator is the presence of a granulomatous inflammatory infiltrate in the dermis and/or hypodermis; this infiltrate is mainly composed of macrophages grouped into nodules having a nodular, palisaded or interstitial architecture. Finally, we propose which diagnostic procedure should be performed when facing a patient with a suspected cutaneous granulomatosis.

Lo Schiavo A, Ruocco E, Gambardella A, O’Leary RE, Gee S (2014) Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol 32(5):646–653. https://doi.org/10.1016/j.clindermatol.2014.04.012 PubMedCrossRef

Asai J (2017) What is new in the histogenesis of granulomatous skin diseases? J Dermatol 44(3):297–303. https://doi.org/10.1111/1346-8138.13662 PubMedCrossRef

Lapointe A-K, Laffitte E (2009) Disseminated cutaneous granulomatosis. Rev Med Suisse 5(900):902–906

Masson E Granulomes cutanés non infectieux. In: EM-Consulte. http://www.em-consulte.com/article/195548/granulomes-cutanes-non-infectieux. Accessed 16 Nov 2017

Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1–14. https://doi.org/10.1093/intimm/dxh186 PubMedCrossRef

Takeda K, Akira S (2015) Toll-like receptors. Curr Protoc Immunol 109:14.12.1–14.1210. https://doi.org/10.1002/0471142735.im1412s109 CrossRef

Ito T, Connett JM, Kunkel SL, Matsukawa A (2013) The linkage of innate and adaptive immune response during granulomatous development. Front Immunol 4:10. https://doi.org/10.3389/fimmu.2013.00010 PubMedPubMedCentralCrossRef

Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229(2):176–185. https://doi.org/10.1002/path.4133 PubMedCrossRef

Boros DL (1978) Granulomatous inflammations. Prog Allergy 24:183–267PubMed

10.

Boros DL (2013) New perspectives on ancient granulomas. Front Immunol 4:345. https://doi.org/10.3389/fimmu.2013.00345 PubMedPubMedCentralCrossRef

11.

Pieters J (2008) Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3(6):399–407. https://doi.org/10.1016/j.chom.2008.05.006 PubMedCrossRef

12.

Hessian PA, Highton J, Kean A, Sun CK, Chin M (2003) Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 48(2):334–338. https://doi.org/10.1002/art.10776 PubMedCrossRef

13.

Okamoto Yoshida Y, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K, Hara H, Nakae S, Iwakura Y, Matsuzaki G (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol Baltim Md 1950 184(8):4414–4422. https://doi.org/10.4049/jimmunol.0903332

14.

Anthony RM, Rutitzky LI, Urban JF, Stadecker MJ, Gause WC (2007) Protective immune mechanisms in helminth infection. Nat Rev Immunol 7(12):975–987. https://doi.org/10.1038/nri2199 PubMedPubMedCentralCrossRef

15.

Friedman SJ, Winkelmann RK (1987) Familial granuloma annulare. Report of two cases and review of the literature. J Am Acad Dermatol 16(3):600–605. https://doi.org/10.1016/S0190-9622(87)70080-2 PubMedCrossRef

16.

Knoell KA (2009) Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype. Arch Dermatol 145(5):610–611. https://doi.org/10.1001/archdermatol.2009.92 PubMedCrossRef

17.

Piette EW, Rosenbach M (2016) Granuloma annulare: clinical and histologic variants, epidemiology, and genetics. J Am Acad Dermatol 75(3):457–465. https://doi.org/10.1016/j.jaad.2015.03.054 PubMedCrossRef

18.

Avitan-Hersh E, Sprecher H, Ramon M, Bergman R (2013) Does infection play a role in the pathogenesis of granuloma annulare? J Am Acad Dermatol 68(2):342–343. https://doi.org/10.1016/j.jaad.2012.08.023 PubMedCrossRef

19.

Piette EW, Rosenbach M (2016) Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol 75(3):467–479. https://doi.org/10.1016/j.jaad.2015.03.055 PubMedCrossRef

20.

Kapoor R, Piris A, Saavedra AP, Duncan LM, Nazarian RM (2013) Wolf isotopic response manifesting as postherpetic granuloma annulare: a case series. Arch Pathol Lab Med 137(2):255–258. https://doi.org/10.5858/arpa.2011-0643-OA PubMedCrossRef

21.

Terziroli Beretta-Piccoli B, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, Invernizzi P, Gershwin ME, Mainetti C (2017) Primary biliary cholangitis associated with skin disorders: a case report and review of the literature. Arch Immunol Ther Exp 65(4):299–309. https://doi.org/10.1007/s00005-016-0448-0 CrossRef

22.

Terziroli Beretta-Piccoli B, Invernizzi P, Gershwin ME, Mainetti C (2017) Skin manifestations associated with autoimmune liver diseases: a systematic review. Clin Rev Allergy Immunol 53(3):394–412. https://doi.org/10.1007/s12016-017-8649-9 PubMedCrossRef

23.

Wu W, Robinson-Bostom L, Kokkotou E, Jung HY, Kroumpouzos G (2012) Dyslipidemia in granuloma annulare: a case-control study. Arch Dermatol 148(10):1131–1136. https://doi.org/10.1001/archdermatol.2012.1381 PubMedCrossRef

24.

Marcoval J, Gómez-Armayones S, Valentí-Medina F, Bonfill-Ortí M, Martínez-Molina L (2015) Necrobiosis lipoidica: a descriptive study of 35 cases. Actas Dermosifiliogr 106(5):402–407. https://doi.org/10.1016/j.ad.2015.01.004 PubMedCrossRef

25.

Muller SA, Winkelmann RK (1966) Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol 93(3):272–281. https://doi.org/10.1001/archderm.1966.01600210008002 PubMedCrossRef

26.

O’Toole EA, Kennedy U, Nolan JJ et al (1999) Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 140(2):283–286. https://doi.org/10.1046/j.1365-2133.1999.02663.x PubMedCrossRef

27.

Kota SK, Jammula S, Kota SK et al (2012) Necrobiosis lipoidica diabeticorum: a case-based review of literature. Indian J Endocrinol Metab 16(4):614–620. https://doi.org/10.4103/2230-8210.98023 PubMedPubMedCentralCrossRef

28.

Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A (2013) Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 69(5):783–791. https://doi.org/10.1016/j.jaad.2013.05.034 PubMedCrossRef

29.

Boateng B, Hiller D, Albrecht HP, Hornstein OP (1993) Cutaneous microcirculation in pretibial necrobiosis lipoidica. Comparative laser Doppler flowmetry and oxygen partial pressure determinations in patients and healthy probands. Hautarzt Z Dermatol Venerol Verwandte Geb 44:581–586

30.

Ngo B, Wigington G, Hayes K, Huerter C, Hillman B, Adler M, Rendell M (2008) Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol 47(4):354–358. https://doi.org/10.1111/j.1365-4632.2008.03549.x PubMedCrossRef

31.

Holland C, Givens V, Smoller BR (2001) Expression of the human erythrocyte glucose transporter Glut-1 in areas of sclerotic collagen in necrobiosis lipoidica. J Cutan Pathol 28(6):287–290. https://doi.org/10.1034/j.1600-0560.2001.028006287.x PubMedCrossRef

32.

Wakusawa C, Fujimura T, Kambayashi Y, Furudate S, Hashimoto A, Aiba S (2013) Pigmented necrobiosis lipoidica accompanied by insulin-dependent diabetes mellitus induces CD163⁺ proinflammatory macrophages and interleukin-17-producing cells. Acta Derm Venereol 93(4):475–476. https://doi.org/10.2340/00015555-1502 PubMedCrossRef

33.

Chua-Aguilera CJ, Möller B, Yawalkar N (2017) Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53(3):371–393. https://doi.org/10.1007/s12016-017-8632-5 PubMedCrossRef

34.

Ali MM, Atwan AA, Gonzalez ML (2010) Cutaneous sarcoidosis: updates in the pathogenesis. J Eur Acad Dermatol Venereol JEADV 24(7):747–755. https://doi.org/10.1111/j.1468-3083.2009.03517.x PubMedCrossRef

35.

Ina Y, Takada K, Yamamoto M, Morishita M, Senda Y, Torii Y (1989) HLA and sarcoidosis in the Japanese. Chest 95(6):1257–1261. https://doi.org/10.1378/chest.95.6.1257 PubMedCrossRef

36.

Ishihara M, Ohno S (1997) Genetic influences on sarcoidosis. Eye Lond Engl 11(Pt 2):155–161. https://doi.org/10.1038/eye.1997.44

37.

Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, Bresnitz E, Rossman M, Thompson B, Rybicki B, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Cherniack R, ACCESS Research Group (2005) Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med 47(3):226–234. https://doi.org/10.1097/01.jom.0000155711.88781.91 PubMedCrossRef

38.

Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, Culver DA, Caprioli RM, Drake WP (2012) Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol 32(5):1129–1140. https://doi.org/10.1007/s10875-012-9700-5 PubMedPubMedCentralCrossRef

39.

Brownell I, Ramírez-Valle F, Sanchez M, Prystowsky S (2011) Evidence for mycobacteria in sarcoidosis. Am J Respir Cell Mol Biol 45(5):899–905. https://doi.org/10.1165/rcmb.2010-0433TR PubMedPubMedCentralCrossRef

40.

Eishi Y (2013) Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int 2013:935289–935218. https://doi.org/10.1155/2013/935289 PubMedPubMedCentralCrossRef

41.

Judson MA, Marchell RM, Mascelli M et al (2012) Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol 66(6):901–910, 910.e1–2. https://doi.org/10.1016/j.jaad.2011.06.017 PubMedCrossRef

42.

Petroianni A, Halili I, Lagalla M, Mougkaraki E, Terzano C (2015) Sarcoidosis at onset of psoriasis: a common immunopathogenesis. Review and case report. Eur Rev Med Pharmacol Sci 19(10):1773–1778PubMed

43.

Rosenbach M, English JC (2015) Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification. Dermatol Clin 33(3):373–387. https://doi.org/10.1016/j.det.2015.03.005 PubMedCrossRef

44.

Ehlers S, Schaible UE (2012) The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol 3:411. https://doi.org/10.3389/fimmu.2012.00411 PubMed

45.

Guirado E, Schlesinger LS, Kaplan G (2013) Macrophages in tuberculosis: friend or foe. Semin Immunopathol 35(5):563–583. https://doi.org/10.1007/s00281-013-0388-2 PubMedPubMedCentralCrossRef

46.

Lugo-Villarino G, Vérollet C, Maridonneau-Parini I, Neyrolles O (2011) Macrophage polarization: convergence point targeted by mycobacterium tuberculosis and HIV. Front Immunol 2:43. https://doi.org/10.3389/fimmu.2011.00043 PubMedPubMedCentralCrossRef

47.

Shaler CR, Horvath CN, Jeyanathan M, Xing Z (2013) Within the enemy’s camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis. Front Immunol 4:30. https://doi.org/10.3389/fimmu.2013.00030 PubMedPubMedCentralCrossRef

48.

Kalen JE, Shokeen D, Ramos-Caro F, Motaparthi K (2017) Palisaded neutrophilic granulomatous dermatitis: spectrum of histologic findings in a single patient. JAAD Case Rep 3(5):425–428. https://doi.org/10.1016/j.jdcr.2017.06.010 PubMedPubMedCentralCrossRef

49.

Dahl MV (2007) Granuloma annulare: long-term follow-up. Arch Dermatol 143(7):946–947. https://doi.org/10.1001/archderm.143.7.946 PubMedCrossRef

50.

Li A, Hogan DJ, Sanusi ID, Smoller BR (2003) Granuloma annulare and malignant neoplasms. Am J Dermatopathol 25(2):113–116. https://doi.org/10.1097/00000372-200304000-00004 PubMedCrossRef

51.

Peyrí J, Moreno A, Marcoval J (2007) Necrobiosis lipoidica. Semin Cutan Med Surg 26(2):87–89. https://doi.org/10.1016/j.sder.2007.02.004 PubMedCrossRef

52.

Bakos RM, Cartell A, Bakos L (2012) Dermatoscopy of early-onset necrobiosis lipoidica. J Am Acad Dermatol 66(4):e143–e144. https://doi.org/10.1016/j.jaad.2011.01.028 PubMedCrossRef

53.

Lim C, Tschuchnigg M, Lim J (2006) Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica. J Cutan Pathol 33(8):581–583. https://doi.org/10.1111/j.1600-0560.2006.00487.x PubMedCrossRef

54.

Mistry BD, Alavi A, Ali S, Mistry N (2017) A systematic review of the relationship between glycemic control and necrobiosis lipoidica diabeticorum in patients with diabetes mellitus. Int J Dermatol 56(12):1319–1327. https://doi.org/10.1111/ijd.13610 PubMedCrossRef

55.

Peckruhn M, Tittelbach J, Elsner P (2017) Update: treatment of necrobiosis lipoidica. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 15(2):151–157. https://doi.org/10.1111/ddg.13186

56.

Durupt F, Dalle S, Debarbieux S, Balme B, Ronger S, Thomas L (2008) Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 144(1):118–119. https://doi.org/10.1001/archderm.144.1.118 PubMedCrossRef

57.

Eberle FC, Ghoreschi K, Hertl M (2010) Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies. Acta Derm Venereol 90(1):104–106. https://doi.org/10.2340/00015555-0757 PubMedCrossRef

58.

Gambichler T, Kreuter A, Freitag M, Pawlak FM, Brockmeyer NH, Altmeyer P (2003) Clearance of necrobiosis lipoidica with fumaric acid esters. Dermatol Basel Switz 207(4):422–424. https://doi.org/10.1159/000074133 CrossRef

59.

Sayah A, English JC (2005) Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 53(2):191–209; quiz 210-212. https://doi.org/10.1016/j.jaad.2004.07.023 PubMedCrossRef

60.

Sibbitt WL, Williams RC (1982) Cutaneous manifestations of rheumatoid arthritis. Int J Dermatol 21(10):563–572. https://doi.org/10.1111/j.1365-4362.1982.tb02037.x PubMedCrossRef

61.

Molina-Ruiz AM, Requena L (2015) Foreign body granulomas. Dermatol Clin 33(3):497–523. https://doi.org/10.1016/j.det.2015.03.014 PubMedCrossRef

62.

Alcântara CEP, Noronha MS, Cunha JF, Flores IL, Mesquita RA (2017) Granulomatous reaction to hyaluronic acid filler material in oral and perioral region: a case report and review of literature. J Cosmet Dermatol. https://doi.org/10.1111/jocd.12374

63.

Ledon JA, Savas JA, Yang S, Franca K, Camacho I, Nouri K (2013) Inflammatory nodules following soft tissue filler use: a review of causative agents, pathology and treatment options. Am J Clin Dermatol 14(5):401–411. https://doi.org/10.1007/s40257-013-0043-7 PubMedCrossRef

64.

Christianson JC, Engber W, Andes D (2003) Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol 41(3):177–188. https://doi.org/10.1080/1369378031000137224 PubMedCrossRef

65.

van Zyl L, du Plessis J, Viljoen J (2015) Cutaneous tuberculosis overview and current treatment regimens. Tuberc Edinb Scotl 95(6):629–638. https://doi.org/10.1016/j.tube.2014.12.006 CrossRef

66.

Schmied E, Schmied C, Mainetti C (1990) Cutaneous manifestations of tuberculosis. Schweiz Rundsch Med Prax Rev Suisse Med Prax 79:1244–1249

67.

Oryan A, Akbari M (2016) Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med 9(10):925–932. https://doi.org/10.1016/j.apjtm.2016.06.021 PubMedCrossRef

68.

Oliveira-Ribeiro C, Pimentel MIF, De Oliveira RVC et al (2017) Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study. BMC Infect Dis 17(1):559. https://doi.org/10.1186/s12879-017-2658-4 PubMedPubMedCentralCrossRef

69.

Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR (2004) Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 90(4):853–859. https://doi.org/10.1645/GE-185R PubMedCrossRef

70.

Negi AK, Sharma NL, Mahajan VK et al (2007) Comparative efficacy of intralesional sodium stibogluconate (SSG) alone and its combination with intramuscular SSG to treat localized cutaneous leishmaniasis: results of a pilot study. Indian J Dermatol Venereol Leprol 73:280PubMed

71.

Munir A, Janjua SA, Hussain I (2008) Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerol Croat ADC 16(2):60–64PubMed

72.

Treatment of Skin Disease - 4th Edition. https://www.elsevier.com/books/treatment-of-skin-disease/lebwohl/978-0-7020-5235-4. Accessed 6 Dec 2017

73.

Lamb RC, Dawn G (2014) Cutaneous non-tuberculous mycobacterial infections. Int J Dermatol 53(10):1197–1204. https://doi.org/10.1111/ijd.12528 PubMedCrossRef

74.

Gray SF, Smith RS, Reynolds NJ, Williams EW (1990) Fish tank granuloma. BMJ 300(6731):1069–1070. https://doi.org/10.1136/bmj.300.6731.1069 PubMedPubMedCentralCrossRef

75.

Eberst E, Dereure O, Guillot B, Trento C, Terru D, van de Perre P, Godreuil S (2012) Epidemiological, clinical, and therapeutic pattern of Mycobacterium marinum infection: a retrospective series of 35 cases from southern France. J Am Acad Dermatol 66(1):e15–e16. https://doi.org/10.1016/j.jaad.2011.01.024 PubMedCrossRef

76.

Garzoni C, Adler S, Boller C, Furrer H, Villiger PM (2010) Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection. Rheumatol Oxf Engl 49(10):1991–1993. https://doi.org/10.1093/rheumatology/keq146 CrossRef

77.

Aubry A, Chosidow O, Caumes E, Robert J, Cambau E (2002) Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 162(15):1746–1752. https://doi.org/10.1001/archinte.162.15.1746 PubMedCrossRef

78.

Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW (2006) Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol 142(10):1287–1292. https://doi.org/10.1001/archderm.142.10.1287 PubMedCrossRef

79.

Drage LA, Ecker PM, Orenstein R, Phillips PK, Edson RS (2010) An outbreak of Mycobacterium chelonae infections in tattoos. J Am Acad Dermatol 62(3):501–506. https://doi.org/10.1016/j.jaad.2009.03.034 PubMedCrossRef

80.

Carbonne A, Brossier F, Arnaud I, Bougmiza I, Caumes E, Meningaud JP, Dubrou S, Jarlier V, Cambau E, Astagneau P (2009) Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol 47(6):1961–1964. https://doi.org/10.1128/JCM.00196-09 PubMedPubMedCentralCrossRef

81.

Gousseff M, Mechaï F, Lecuit M, Lortholary O (2008) Systemic granulomatosis of infectious origin. Rev Med Interne 29(1):15–27. https://doi.org/10.1016/j.revmed.2007.09.037 PubMedCrossRef

82.

Degitz K, Steidl M, Thomas P, Plewig G, Volkenandt M (1993) Aetiology of tuberculids. Lancet Lond Engl 341(8839):239–240. https://doi.org/10.1016/0140-6736(93)90101-L CrossRef

83.

Gupta V (2015) Papulonecrotic tuberculid with scrofuloderma: an uncommon association. J Clin Diagn Res JCDR 9:WD03–WD04. https://doi.org/10.7860/JCDR/2015/10751.5524 PubMed

84.

Greuter T, Navarini A, Vavricka SR (2017) Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 53(3):413–427. https://doi.org/10.1007/s12016-017-8617-4 PubMedCrossRef

85.

Wanat KA, Rosenbach M (2014) A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol 15(4):283–297. https://doi.org/10.1007/s40257-014-0079-3 PubMedCrossRef

86.

Giner T, Benoit S, Kneitz H, Goebeler M (2017) Sarcoidosis: dermatological view of a rare multisystem disease. Hautarzt Z Dermatol Venerol Verwandte Geb 68(7):526–535. https://doi.org/10.1007/s00105-017-4005-5 CrossRef

87.

Tchernev G (2006) Cutaneous sarcoidosis: the “great imitator”: etiopathogenesis, morphology, differential diagnosis, and clinical management. Am J Clin Dermatol 7(6):375–382. https://doi.org/10.2165/00128071-200607060-00006 PubMedCrossRef

88.

Tchernev G, Patterson JW, Nenoff P, Horn LC (2010) Sarcoidosis of the skin—a dermatological puzzle: important differential diagnostic aspects and guidelines for clinical and histopathological recognition. J Eur Acad Dermatol Venereol JEADV 24(2):125–137. https://doi.org/10.1111/j.1468-3083.2009.03396.x PubMedCrossRef

89.

Haimovic A, Sanchez M, Judson MA, Prystowsky S (2012) Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 66(5):699.e1–699.18; quiz 717-718. https://doi.org/10.1016/j.jaad.2011.11.965 CrossRef

90.

Mañá J, Marcoval J (2012) Skin manifestations of sarcoidosis. Presse Medicale Paris Fr 1983 41(6):e355–e374. https://doi.org/10.1016/j.lpm.2012.02.046

91.

Spiteri MA, Matthey F, Gordon T et al (1985) Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 112(3):315–322. https://doi.org/10.1111/j.1365-2133.1985.tb04859.x PubMedCrossRef

92.

Marcoval J, Mañá J, Rubio M (2011) Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol 36(7):739–744. https://doi.org/10.1111/j.1365-2230.2011.04128.x PubMedCrossRef

93.

Veien NK, Stahl D, Brodthagen H (1987) Cutaneous sarcoidosis in Caucasians. J Am Acad Dermatol 16(3):534–540. https://doi.org/10.1016/S0190-9622(87)70070-X PubMedCrossRef

94.

Heath CR, David J, Taylor SC (2012) Sarcoidosis: are there differences in your skin of color patients? J Am Acad Dermatol 66(1):121.e1–121.14. https://doi.org/10.1016/j.jaad.2010.06.068 CrossRef

95.

Rybicki BA, Iannuzzi MC (2007) Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med 28(1):22–35. https://doi.org/10.1055/s-2007-970331 PubMedCrossRef

96.

Rybicki BA, Major M, Popovich J, Maliank MJ, lannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241. https://doi.org/10.1093/oxfordjournals.aje.a009096 PubMedCrossRef

97.

Young RJ, Gilson RT, Yanase D, Elston DM (2001) Cutaneous sarcoidosis. Int J Dermatol 40(4):249–253. https://doi.org/10.1046/j.1365-4362.2001.01151.x PubMedCrossRef

98.

Aubart FC, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, Nunes H (2006) Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore) 85(6):365–371. https://doi.org/10.1097/01.md.0000236955.79966.07 CrossRef

99.

Baughman RP, Lower EE (2015) Treatment of sarcoidosis. Clin Rev Allergy Immunol 49(1):79–92. https://doi.org/10.1007/s12016-015-8492-9 PubMedCrossRef

100.

Baughman RP, Lower EE (2007) Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 25(3):334–340. https://doi.org/10.1016/j.clindermatol.2007.03.011 PubMedCrossRef

101.

Kouba DJ, Mimouni D, Rencic A, Nousari HC (2003) Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148(1):147–148. https://doi.org/10.1046/j.1365-2133.2003.05042.x PubMedCrossRef

102.

Stagaki E, Mountford WK, Lackland DT, Judson MA (2009) The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 135(2):468–476. https://doi.org/10.1378/chest.08-1347 PubMedCrossRef

103.

Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137(1):69–73PubMedCrossRef

104.

Baughman RP, Judson MA, Lower EE et al (2016) Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 32:289–295

105.

Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, Caux F, Chapelon-Abric C, Debarbieux S, Delaporte E, Duval-Modeste AB, Fain O, Joly P, Marchand-Adam S, Monfort JB, Noël N, Passeron T, Ruivard M, Sarrot-Reynauld F, Verrot D, Bouvry D, Fardet L, Chosidow O, Sève P, Valeyre D (2017) Efficacy and tolerance of anti-tumor necrosis factor α agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol 153(7):681–685. https://doi.org/10.1001/jamadermatol.2017.1162 PubMedCrossRef

106.

Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE (2012) Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 148(2):262–264. https://doi.org/10.1001/archdermatol.2011.301 PubMedCrossRef

107.

Baughman RP, Lower EE (2004) Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 5(6):385–394. https://doi.org/10.2165/00128071-200405060-00003 PubMedCrossRef

108.

Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbé C, Morel P, Rybojad M (2004) Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 50(2):235–241. https://doi.org/10.1016/j.jaad.2003.07.006 PubMedCrossRef

109.

Bohelay G, Bouaziz J-D, Nunes H, Rybojad M, Bagot M, Petit A, Laroche L (2014) Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J Am Acad Dermatol 70(5):e111–e113. https://doi.org/10.1016/j.jaad.2013.10.048 PubMedCrossRef

110.

Israel HL, McComb BL (1991) Chlorambucil treatment of sarcoidosis. Sarcoidosis 8(1):35–41PubMed

111.

Baughman RP, Lower EE (2004) Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 21:43–48

112.

Ackerman AB, Guo Y, Vitale PA, Vossaert K (1993) Clues to diagnosis in dermatopathology, vol 3. ASCP Press, Chicago, pp 309–312

113.

Verneuil L, Dompmartin A, Comoz F, Pasquier CJ, Leroy D (2001) Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies. J Am Acad Dermatol 45(2):286–291. https://doi.org/10.1067/mjd.2001.114577 PubMedCrossRef

114.

Wang Y, Wu Y, Zheng Z, Bai Y, Cui Y (2017) Interstitial granulomatous dermatitis associated with primary biliary cirrhosis. J Dermatol. https://doi.org/10.1111/1346-8138.13778

115.

Schreckenberg C, Asch PH, Sibilia J, Walter S, Lipsker D, Heid E, Grosshans E (1998) Interstitial granulomatous dermatitis and paraneoplastic rheumatoid polyarthritis disclosing cancer of the lung. Ann Dermatol Venereol 125(9):585–588PubMed

116.

Dodiuk-Gad RP, Shear NH (2015) Granulomatous drug eruptions. Dermatol Clin 33(3):525–539. https://doi.org/10.1016/j.det.2015.03.015 PubMedCrossRef

117.

Perrin C, Lacour JP, Castanet J, Michiels JF (2001) Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol 23(4):295–298. https://doi.org/10.1097/00000372-200108000-00003 PubMedCrossRef

118.

Gerbing EK, Metze D, Luger TA, Ständer S (2003) Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 1:137–141

119.

Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A (2006) Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 142(2):198–202. https://doi.org/10.1001/archderm.142.2.198 PubMedCrossRef

120.

Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kötter I, Fierlbeck G (2012) Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol 148(1):17–20. https://doi.org/10.1001/archdermatol.2011.341 PubMedCrossRef

Title: Cutaneous Granulomatosis: a Comprehensive Review
Authors: Benedetta Terziroli Beretta-Piccoli
Carlo Mainetti
Marie-Astrid Peeters
Emmanuel Laffitte
Publication date: 01-02-2018
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2018
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-017-8666-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cutaneous Granulomatosis: a Comprehensive Review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Current Perspectives on Erythema Multiforme

Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management

Dermatological Complications After Solid Organ Transplantation

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Urticaria and Angioedema: an Update on Classification and Pathogenesis

A Comprehensive Review of Neutrophilic Diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page